Cadrenal Therapeutics Inc. (CVKD) News
Filter CVKD News Items
CVKD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CVKD News Highlights
- CVKD's 30 day story count now stands at 2.
- Over the past 7 days, the trend for CVKD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- SAGE are the most mentioned tickers in articles about CVKD.
Latest CVKD News From Around the Web
Below are the latest news stories about CADRENAL THERAPEUTICS INC that investors may wish to consider to help them evaluate CVKD as an investment opportunity.
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price TargetCadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain orphan diseases, today announced that Noble Capital Markets ("Noble") has initiated equity research coverage on the Company with an "Outperform" rating and a price target of US$4.00 per share. The full report by Noble Capital Markets Sen |
Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and CommercializationCadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage, novel, oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths (due to blood clots in patients with certain orphan diseases), today announced an engagement with The Sage Group (www.sagehealthcare.com) to assist the company in exploring strategic partnerships, co-development and licensing agreements for tecarfarin. |
Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham, CEO, will present at NobleCon19 - Noble Capital Markets' Nineteenth (19) Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in B |
Cadrenal Therapeutics Provides Third Quarter 2023 Corporate UpdateCadrenal Therapeutics, Inc., (Nasdaq: CVKD) ("Cadrenal Therapeutics" or the "Company") a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. |
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor ConferenceCadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham, CEO, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023. Management will also be c |
Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology CongressCadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today cited recent data that underscores additional need for an improved Vitamin K Antagonist (VKA). The Company believes tecarfarin is the solution for this unmet need. |
Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today announced the expanded evaluation of tecarfarin for the treatment of patients with antiphospholipid syndrome (APS) who require chronic anticoagulation. |
Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceCadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today announced that its Founder, Chairman, and CEO Quang Pham; CFO Matthew Szot; and CMO, Dr. Douglas Losordo, will be participating in the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually an |
Cadrenal Therapeutics Provides Second Quarter 2023 Corporate UpdateCadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023. |
Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart DiseasesCadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced that the Company is expanding its focus for tecarfarin to patients with implanted medical devices for heart diseases who are struggling with the lack of effective anticoagulant treatment options. |